An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction

International Journal of Clinical Practice

Volumn 67, Issue 4, 2013, Pages 333-341

  Belkoff, L H ^a   McCullough, A ^b   Goldstein, I ^c   Jones, L ^d   Bowden, C H ^e   Didonato, K ^e   Trask, B ^e   Day, W W ^e  

^a Urologic Consultants of Southeastern Pennsylvania   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c ALVARADO HOSPITAL   (United States)

^d Urology San Antonio   (United States)

^e Menlo Park and VIVUS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVANAFIL; PLACEBO;

ADULT; AGE; AGED; ARTICLE; BACKACHE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FAINTNESS; FLUSHING; HEARING IMPAIRMENT; HUMAN; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE OBSTRUCTION; OPEN STUDY; PENIS ERECTION; PHASE 3 CLINICAL TRIAL; PRIAPISM; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEXUAL INTERCOURSE; SIDE EFFECT;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOSPHODIESTERASE 5 INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84875485911     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12065     Document Type: Article

References (22)

1. Selvin E, Burnett AL, Platz EA,. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151-7.
2. Feldman H, Goldstein I, Hatzichristou DG, et al., Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
3. Johannes CB, Araujo AB, Feldman HA, et al., Incidence of erectile dysfunction in men 40-69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460-3.
4. Corbin JD,. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 2004; 16 (Suppl 1): S4-7.
5. Corona G, Mondaini N, Ungar A, et al., Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8: 3418-32.
6. Schouten BW, Bohnen AM, Groeneveld FP, et al., Erectile dysfunction in the community: trends over time in incidence, prevalence, GP consultation and medication use-the Krimpen study: trends in ED. J Sex Med 2010; 7: 2547-53.
7. Eardley I, Donatucci C, Corbin J, et al., Pharmacotherapy for erectile dysfunction. J Sex Med 2010; 7 (1 Pt 2): 524-40.
8. Pfizer Labs. Viagra (package insert). New York, NY: Pfizer Labs, 2010.
9. Eli Lilly and Company. Cialis (package insert). Indianapolis, IN: Eli Lilly and Company, 2011.
10. Bayer HealthCare Pharmaceuticals, Inc. Levitra (package insert). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 2011.
11. Bischoff E,. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004; 16: S11-4.
12. Giuliano F, Jackson G, Montorsi F, et al., Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64: 240-55.
13. VIVUS, Inc. STENDRA (package insert). Mountain View, CA: VIVUS, Inc., 2012.
14. Allison M, Grant T, Obaidi M, et al., Pharmacokinetics of avanafil, a novel, rapidly absorbed, selective PDE5 inhibitor for the treatment of mild to severe erectile dysfunction. J Sex Med 2011; 8: S466-7.
15. Goldstein I, McCullough AR, Jones LA, et al., A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9: 1122-33.
16. Hellstrom JG, Freier MT, Serefoglu EC, et al., A phase 2, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. BJU Int 2012; July 12 [Epub ahead of print].
17. Goldstein I, Jones L, Belkoff L, et al., Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes. Mayo Clin Proc 2012; 87: 843-52.
18. Kaufman J, Dietrich J,. Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction. J Sex Med 2006; 3: 14-69.
19. Mulhall JP, Moul JW, Wang R, et al., A phase III, placebo-controlled study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral, nerve-sparing radical prostatectomy. J Sex Med 2012; 9: S42-3.
20. Mulhall JP, Burnett AL, McVary KT, et al. Efficacy and safety of avanafil, a next-generation, phosphodiesterase type 5 inhibitor for the treatment of men with erectile dysfunction: data from phase 2 and 3 studies in difficult-to-treat populations. Oral presentation at: the American Urological Association (AUA) Annual Meeting; 19-23 May 2012; Atlanta, GA, USA.
21. Rosen RC, Riley A, Wagner G, et al., The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
22. Kotera J, Mochida H, Inoue H, et al., Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol 2012; 188: 668-74.